A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF BIRTAMIMAB PLUS STANDARD OF CARE VS. PLACEBO PLUS STANDARD OF CARE IN MAYO STAGE IV SUBJECTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS

Registry ID

NEOD001-301

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

PROTHENA THERAPEUTICS LIMITED

Start date

2023-09-18

Last update

2021-05-12

Conditions

• AMYLOIDOSIS

Related clinical trials

• A PHASE 1B/2 STUDY OF AZD0120 (ALSO KNOWN AS GC012F), A CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY TARGETING CD19 AND B-CELL MATURATION ANTIGEN (BCMA) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY AL AMYLOIDOSIS
• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF INTRATHECALLY ADMINISTERED ALN-APP IN PATIENTS WITH CEREBRAL AMYLOID ANGIOPATHY (CAA)
• A PHASE 2, MULTICOHORT STUDY OF DARATUMUMAB-BASED THERAPIES IN PARTICIPANTS WITH AMYLOID LIGHT CHAIN (AL) AMYLOIDOSIS
• A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAEL-101 AND PLASMA CELL DYSCRASIA TREATMENT VERSUS PLACEBO AND PLASMA CELL DYSCRASIA TREATMENT IN PLASMA CELL DYSCRASIA TREATMENT-NAÏVE PATIENTS WITH MAYO STAGE IIIB AL AMYLOIDOSIS
• A PHASE 3, DOUBLE-BLIND, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAEL-101 AND PLASMA CELL DYSCRASIA TREATMENT VERSUS PLACEBO AND PLASMA CELL DYSCRASIA TREATMENT IN PLASMA CELL DYSCRASIA TREATMENT-NAÏVE PATIENTS WITH MAYO STAGE IIIA AL AMYLOIDOSIS
• A RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DARATUMUMAB IN COMBINATION WITH CYCLOPHOSPHAMIDE, BORTEZOMIB AND DEXAMETHASONE (CYBORD) COMPARED WITH CYBORD ALONE IN NEWLY DIAGNOSED SYSTEMIC AL AMYLOIDOSIS

View on source registry